πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

Showing page 58 of 857 Β· Phase 3 first, then by program name

  1. Duvakitug, matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  2. Dydrogesterone 30 mg

    Abbott Australasia Pty Ltd

    Female Infertility

    phase 3 small molecule completed

    1 trial

  3. Dynepo (Epoetin delta)

    Takeda

    Anemia

    phase 3 small molecule terminated

    1 trial

  4. Dysport Placebo Solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection

    Ipsen

    Chronic migraine

    phase 3 small molecule active

    1 trial

  5. Dysport Placebo Solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection

    Ipsen

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  6. E/C/F/TDF

    Gilead Sciences Ireland UC

    Acquired Immunodeficiency Syndrome

    phase 3 small molecule completed

    1 trial

  7. E004 (Epinephrine Inhalation Aerosol) HFA-MDI

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  8. E0302 (mecobalamin)

    Eisai Co.,

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule completed

    1 trial

  9. E7777 9 mcg/kg

    CITIUS ONCOLOGY, INC.

    Persistent or Recurrent Cutaneous T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  10. EADM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  11. EB-101

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  12. EB-101 Surgical application of RDEB wounds

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  13. EBVALLO

    Pierre Fabre Medicament

    Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease

    phase 3 small molecule active

    1 trial

  14. ECULIZUMAB , ECULIZUMAB

    Pari Pharma GmbH

    Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine β‰₯ 354ΞΌM)

    phase 3 small molecule active

    1 trial

  15. ECULIZUMAB, Crovalimab, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  16. EFG PH20 SC

    argenx

    Active Idiopathic Inflammatory Myopathy

    phase 3 mab active

    1 trial

  17. EFGARTIGIMOD ALFA, JNJ-80202135

    Janssen-Cilag International N.V.

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  18. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  19. EIK1001

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  20. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  21. ELECTROLYTES , VIALEBEX 200 g/L, solution pour perfusion

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  22. ELIGARD 45 mg, poudre et solvant pour solution injectable

    Ningbo Cancer Hospital

    Prostatic adenocarnicoma with high risk of recurrence

    phase 3 small molecule active

    1 trial

  23. ELOXATINE 5 mg/ml, solution Γ  diluer pour perfusion, ELOXATINE 5 mg/ml, solution Γ  diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer and rectal with liver metastasis

    phase 3 small molecule active

    1 trial

  24. ELRANATAMAB

    Pfizer Australia Pty Ltd

    Multiple myeloma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources